<DOC>
	<DOC>NCT01018914</DOC>
	<brief_summary>To compare the safety and efficacy of Prograf速 with Myfortic速 to Advagraf速 extended release tacrolimus with Myfortic速 in de novo liver transplant recipients.</brief_summary>
	<brief_title>A Study to Compare Safety and Efficacy of Prograf + Myfortic and Advagraf + Myfortic in Liver Transplantation Patients</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Patient is a primary liver transplant recipient Female patients of child bearing potential must have a negative urine or serum pregnancy test within 7 days prior to transplant Patient has been fully informed and has signed an IRB approved informed consent form and is willing and able to follow study procedures Patient must receive 1st dose of study drug within 24 hours of pretransplantation Patient has previously received or is receiving an organ transplant other than a liver Patient currently requires dialysis Patient has received a liver transplant from a nonheart beating donor Patient has received an ABO incompatible donor liver Recipient or donor is known to be seropositive for human immunodeficiency virus (HIV) Patient has fulminant hepatic failure, unless hemodynamically stable Patient has an uncontrolled concomitant infection, a systemic infection requiring treatment (except viral hepatitis), or any other unstable medical condition that could interfere with the study objectives Patient is currently taking or has been taking an investigational drug in the 30 days prior to transplant Patient has a known hypersensitivity to tacrolimus, entericcoated mycophenolate sodium or corticosteroids Patient is pregnant or lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Prograf</keyword>
	<keyword>Advagraf</keyword>
	<keyword>Myfortic</keyword>
</DOC>